AcelRx pulls in $250M for opioid drug-device combo Zalviso; Unilife signs deal for its Ocu-Jet eye drug delivery system;

> AcelRx ($ACRX) teamed up with Germany's Grunenthal to develop its late-stage opioid drug-device combination Zalviso in Europe. AcelRx will pick up $30 million up front and up to $220 million in milestone payments moving forward. Story

> Unilife ($UNIS) signed an agreement with a "global pharmaceutical company" for the use of Unilife's Ocu-Jet delivery system for injectable treatments in the eye. Unilife has forged several high-profile partnerships in recent months. Release

> Researchers at Western University are working on a delivery nanostructure to carry pain meds directly to bones. More

> OncoSec Medical heralded positive Phase II data for its immunotherapy to treat solid tumors. The treatment uses the company's electroporation technology to deliver the cancer drug directly into the tumor. Release

> Moberg Pharma reported positive interim Phase II results of its topical formulation for the treatment of nail fungus. Release

> Insite Vision announced positive Phase III results for its eye drops to reduce inflammation and pain after cataract surgery. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.